Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Active not recruiting × Neoplasms × Tamoxifen × Clear all

Phase

Status

Completed 5 Terminated 2 Unknown 1 Recruiting 1 Not yet recruiting 1 Enrolling by invitation 1 Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 20 Carcinoma, Intraductal, Noninfiltrating 3 Ovarian Neoplasms 2 Breast Cancer Female 2 Prostatic Neoplasms 1 Premenopausal Breast Cancer 1 Pancreatic Neoplasms 1 Neoplasms 1 Neoplasm Recurrence, Local 1 Neoplasm Metastasis 1 Carcinoma, Lobular 1 Breast Neoplasms, Male 1 Breast Carcinoma In Situ 1 Breast Cancer Subjects 1

Interventions

pembrolizumab 27 Cyclophosphamide 17 Nivolumab 16 fludarabine 8 Surveys and Questionnaires 8 Paclitaxel 8 Exercise 8 Doxorubicin 8 Carboplatin 8 Bevacizumab 8 budigalimab 7 atezolizumab 7 Radiotherapy 7 Fluorouracil 7 Docetaxel 7 Dexamethasone 7 Blood Specimen Collection 7 venetoclax 6 lenvatinib 6 cabozantinib 6 Rituximab 6 Prednisone 6 Pemetrexed 6 Oxaliplatin 6 Gemcitabine 6 fludarabine phosphate 5 durvalumab 5 avelumab 5 Vincristine 5 Leucovorin 5

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04906395 2026-01-13

OVELIA

Tolmar Inc.

Phase 3 Active not recruiting

Breast Neoplasms, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡